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ABSTRACT

CORRELATION OF THE SIGNS AND SYMPTOMS OF UTERINE
LEIOMYOMAS

WITH THE FINDINGS ON MAGNETIC RESONANCE
IMAGING

Symphorosa

STUDIE5.

Magdaleine

Williams

1991

This study was designed to investigate any correlation between the
symptoms and signs of uterine leiomyomas and magnetic resonance imaging
(MRi) findings. The symptoms and signs reported at each visit were recorded
from a review of the clinical charts of 45 patients. 1 14MR1 studies, 93 of
which were performed within 0-30 days, and 16 of which were performed
within 30-51 days of the corresponding clinical visit, were reviewed by an
investigator, biinded to the clinical

data. Total

uterine volume,

total

leiomyoma volume, and the uterine and leiomyoma MR! characteristics were
assessed. Thirty-one patients, with a total of 47 MRi studies, received
leuproiide acetate (LA) during the period of review. These were examined as
a separate group, and compared with the “no drug" group. Junctional zone
(JZ) disruption did not correlate with the presence of menorrhagia or
metrorrhagia (p > 0.05) in either patient group. LA decreased the Incidence
of menorrhagia (p < 0.0005), but had no effect on metrorrhagia (p > 0.05). JZ
disruption did not correlate with spontaneous abortion or Infertility (p >
0.1). The leiomyoma location (uterine body, fundus, cervix, broad ligament,
multiple) did not affect the incidence of pressure (p > 0.1), abdominal/pelvic

(A/'P) pain (p > 0.1)., Pack pain (p > 0.1), or infertility (p > 0.5). LA decreased
the incidence of pressure only in patients with leiomyomas in the uterine
body (p < 0.05). The leiomyoma type (submucosal, intramural, subserosa!) did
not affect the incidence of infertility (p > 0.05) or spontaneous abortion (p >
0.5). It did not affect dysmenorrhea in LA treated patients (p > 0.55, but
intramural leiomyomas were associated with dysmenorrhea in the no drug
group (p < 0.005). Submucosal and intramural tumors in patients with no
drug treatment were also associated with dysmenorrhea, when compared
with LA treated patients (p < 0.005). Leiomyoma degeneration was dependent
on the tumor volume. Smaller tumors had less degeneration while the larger
tumors had more carneous and non-specific degenerative changes (p

<

0.005). LA had no effect on the incidence of degeneration. A/P pain was
associated with carneous leiomyomas in patients with no drug treatment (p
< 0.05). There was no association between A/P pain or pressure and total
uterine volume (p > 0.1), but LA decreased the incidence of pain in patients
with uterine volumes less than 600 cc (p < 0.005). Uterine non-leiomyoma
volumes were not associated with spontaneous abortion or infertility (p >
0 5). We conclude that most symptoms that have always been attributed to
Individual characteristics of the leiomyomas cannot be directly explained by
them. The only statistically significant relationships occurred between
degeneration and tumor size, and dysmenorrhea and intramural tumors. The
effect of LA in alleviating patient symptoms is again confirmed.
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1.

INTRODUCTION

I. UTERINE LEIOMYOMAS

A. Epidemiology & Etiology
Uterine

leiomyomas,

also

known

as

fibroids,

fibromas,

or

fibromyomas (42), are benign smooth muscle tumors of the uterus.They are
the most common pelvic tumors in women, occurring in one out of four to
five women of reproductive age (9). They occur more frequently in women
over thirty-five years of age (42), and they are responsible for at least
one-third of all gynecological admissions (50). Leiomyomas are also more
common in Black women than in White women (42). The reason for this
racial difference in incidence is not known.
The etiology of these tumors is still not clearly understood. Various
theories

include the probability

that

i.

they

arise

from

groups

of

persistent embryonic cells (42), ii. they arise from the smooth muscle
layers of blood vessels in the myometrium (42), iii. they arise from a
single neoplastic parent smooth muscle cell in the myometrium (9). This
latter theory is supported by the evidence presented by Townsend et al.
who found that cells in each individual leiomyoma had identical glucose6-phosphate dehydrogenase (electrophoretically), although this enzyme
was different in other leiomyomas within the same uterus ( 58 ). Although
the initial etiology of these tumors is not clearly defined, one generally
accepted factor in the

growth of leiomyomas is the effect of estrogen.

Leiomyomas tend to occur in women of reproductive age; they rarely occur

before

menarche,

and

usually

regress

after menopause.

They

also

proliferate during pregnancy, and with the use of birth-control pills, when
serum estrogen levels are high. (42).
separate studies, demonstrated

Wilson et al. and Tamaya et a!., in

a higher concentration

receptors in leiornyomatous tissue than in

of

estrogen

adjoining myometrium in the

same patient (60, 56 ). Other hormones, such as growth hormone and human
placental lactogen have been implicated in a probable synergistic effect
with estrogen on the tumor proliferation (9). This may explain the
increased sensitivity of leiornyomatous tissue to estrogen, and the rapid
growth observed in hyperestrogenic states. There are, however, several
other factors, currently unknown, which contribute to the varying rates of
growth of leiomyomas in different women. Additional studies will be
needed to further clarify the etiology and development of leiomyomas.

B. Histopathologv
Leiomyomas have three main classifications, depending on the layer
of the uterus they originate in. They are called subserosal when they arise
from the myometrium and grow directly beneath the uterine serosa,
projecting into the pelvic cavity (42). Subserosal leiomyomas can become
pedunculated with increased growth and form a migratory leiomyoma (50).
They may remain attached to the uterus by a pedicle, or may attach to
adjacent viscera, peritoneum, or omentum.

In the latter case, the

subserosal leiomyoma may lose its primary blood supply from the uterus,
develop a secondary blood supply from its new attachment, and is then
classified as a parasitic leiomyoma, intraligamentous leiomyomas occur

when the subserosal leiomyoma grows into the broad ligament. Intramural
leiomyomas, the most frequent type of leiomyomas, originate in the
myometrium, and while they may impinge on the uterine serosa or mucosa,
the bulk of the leiomyoma remains in the myometrium. These can also
enlarge, and distort the uterine cavity or the outer uterine surface.
Submucosal leiomyomas arise in the myometrium directly beneath the
endometrium. These may also distort the uterine cavity. They also
occasionally become pedunculated, and can then protrude into the cervix
and vaginal canal where they are prone to infection (42).
Leiomyomas occur most frequently within the uterine corpus (42,
50). They less frequently occur in the lower uterine segment, the cervical
region (50), the isthmus and the cornual regions of the uterus. They can
occur singly, but are often multiple, ranging in size from barely visible
"seedlings" of one centimeter or less, to large masses (42, 50), weighing
as much as 147 lbs (42). They are firm masses, distinct from the
surrounding myometrium. The leiomyomas do not have true capsules, but
are covered by a pseudocapsule, formed by compression of the surrounding
myometrium (42).

Gross pathological inspection shows a characteristic

whorled pattern of smooth muscle bundles (42, 50). Histologically, the
smooth muscle cells of the leiomyomas resemble those of the normal
myometrium, without increased mitotic figures or anaplastic changes
(50). There is fibrous connective tissue interspersed between the smooth
muscle bundles with one or more blood vessels providing nutrients to the
tumors.
Leiomyomas may undergo various degenerative changes. These are
often associated with a relative decrease in blood supply, which usually
occurs with a rapid increase in the growth of the tumors, particularly in
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pregnancy, when there is mechanical disruption of the blood vessels, or
degenerative changes may occur with menopause. (42).

These changes

consist of hyaline, cystic, fatty, carneous, or calcific degeneration.
Hyaline degeneration is the most common type of degenerative change, and
occurs in even small

leiomyomas (42).

Persaud et al.

found hyaline

degeneration in 63% of the 195 leiomyomas that had degenerative changes
(45). The consistency of the tumor changes and becomes softer. On gross
examination, the degenerated areas are pale, homogeneous, and lack the
characteristic whorled appearance. Microscopically, hyaline connective
tissue replaces the smooth muscle cells, and the affected regions appear
amorphous and pinkish-red (45). Hyalinization can further degenerate into
liquefied

areas

(42,45),

which

are

also visible

grossly

-

cystic

degeneration. These cysts lack an epithelium, and may contain colorless or
bloodstained fluid. Myxomatous and mucoid changes can also result in
cystic

degeneration.

Fatty

degeneration

occurs

rarely,

and

is

also

associated with hyaline changes. It is characterized by small vacuolated
fat-containing cells within the tumors (45). Carneous (red) degeneration is
believed to occur in about 8% of leiomyomas complicating pregnancy.
Aseptic necrosis occurs, followed by hemorrhage into the leiomyoma (42).
The tumor becomes mottled, beefy-red and soft, and microscopically a
patchy necrosis associated with hemorrhagic muscle fibers is seen (42,
45). Calcification tends to occur in postmenopausal women, with diffuse
or focal changes within the leiomyoma (42). In extreme cases, the entire
tumor may be converted into a calcified mass (43). Finally sarcomatous
transformation is said to occur in leiomyomas, but this is very rare, less
than 0.5-1% (42, 29). This is not considered to be the natural progression
of leiomyomas, since the incidence of leiomyomas, which is relatively
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high, does not correlate with the Incidence of uterine sarcomas which is
low.

C. Signs, Symptoms & Complications
Uterine

leiomyomas

may

produce

several

different

signs

and

symptoms, or may remain totally asymptomatic. Between 20-50% of all
leiomyomas are symptomatic (9, 29). Abnormal uterine bleeding is the
most prevalent symptom, occurring in about 30% of patients (9, 29). it is
usually manifested as menorrhagia,

with heavy extended

periods

of

menstrual bleeding associated with perimenstrual spotting. Metrorrhagia
also frequently occurs in these patients. This abnormal uterine bleeding
has been attributed to the presence of submucosal leiomyomas causing
thinning and ulceration of the overlying endometrial mucosa (9, 29, 42). In
a study by Fraser et al., submucosal

and

leiomyomas were found most frequently

intrauterine

pedunculated

in patients with

excessive

bleeding (18). However, the incidence of submucosal leiomyomas is not
high enough to account for the frequency of the abnormal uterine bleeding.
Farber-Brown et al. have demonstrated compression of the venous plexi in
the endometrium and myometrium by all three types of leiomyomas. This
causes engorgement and dilation of the vessels, and predisposes the
patient to excessive bleeding during menstruation (15, 16). It is also
believed that the increased endometrial surface area due to protruding
submucosal leiomyomas, and an impairment of uterine contractility by
intramural leiomyomas may contribute to the menorrhagia (42). Patients
may present with an iron deficiency anemia refractory to iron replacement

therapy, or in a hypovolemic state due to excessive and rapid blood loss.
These conditions can require surgical intervention.
Pressure and pain were the presenting symptoms in 34% of patients
with uterine leiomyomas in a review by Buttram et al. (9). Large tumors
may

impinge

incontinence,

on
or

the

urinary

frequency;

bladder,

compression

hydroureters or hydronephrosis,

causing
of

the

urinary
ureters

retention,
can

cause

compression of the pelvic vessels may

cause lower extremity edema or varicosities.

Pressure on the rectum or

intestines may cause constipation and intestinal obstruction (29, 42).
Patients may also complain of a general heaviness in the pelvic region.
Pain often occurs with infection or carneous degeneration of a leiomyoma.
Tumors may impinge on adjacent abdominal and pelvic viscera and nerves,
causing

pain

that

can

radiate

into

the

lower

extremities

(29).

Pedunculated leiomyomas can undergo torsion, infarcting and producing
acute pain (29, 42). Patients may also experience increased dysmenorrhea,
which may be due to cramping caused by submucosal and intramural
leiomyomas (42). Dyspareunia can also

be

associated

with

cervical

leiomyomas (29).
25-35% of patients with uterine leiomyomas are estimated to have
infertility problems (43). Infertility is defined as the inability to conceive
after one year of unprotected intercourse (54). Only about 2-10% of all
cases of infertility can be solely attributed to these tumors (9, 29). There
are usually other associated factors, such as pelvic inflammatory disease,
endometriosis, anovulatory cycles, abnormal tubal and uterine motility,
and various male partner factors (29)

Uterine leiomyomas can cause

infertility in several ways. Cervical and cornual tumors can impinge on the
uterine

and

tubal

lumens,

obstructing

the

passage

of

sperm

(9).
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Submucosal and intramural leiomyomas may cause distortion of the
uterine cavity, which may interfere with sperm passage or implantation of
the fertilized ovum. Submucosal leiomyomas can also cause atrophy and
ulceration of the overlying endometrium, producing an inappropriate milieu
for the implantation and development of the embryo (9).

This can also

predispose the patient to spontaneous abortions. The occurrence of
spontaneous abortions in pregnant women with uterine leiomyomas was
found to be as high as 41% by Buttram et al., compared with an incidence
rate of 10% in the general population. The rate of spontaneous abortions in
women after myomectomies decreased to 19% (9), which is much closer to
that of the general

population. Multiple submucosal

and intramural

leiomyomas can distort, the uterine cavity, and decrease the uterine
volume available for normal development of the fetus, increasing the
chances of a spontaneous abortion.
Once a patient with uterine leiomyomas becomes pregnant, she may
face further problems associated with the tumors. Leiomyomas are
associated with 0.3-7.2% of all pregnancies (42). The leiomyomas are
usually present, and may be asymptomatic before pregnancy, but they tend
to increase in size due to edema, hemorrhage into the tumor (29), and
response to the increased estrogen levels. About 50% of leiomyomas that
are present prior to pregnancy increase in size during the gestational
period. The timing of the growth of the tumors varies depending on the
original tumor size. Smaller leiomyomas tend to grow in the first and
second trimesters, and regress thereafter. Larger tumors grow only during
the first trimester, and regress in the second and third trimesters (32).
The growth of the leiomyomas outstrips the blood supply to the tumors
resulting in infarction, carneous degeneration and pain. Leiomyomas can
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further complicate

pregnancy

by

causing

premature

delivery,

fetal

representation, and dystocia due to cervical tumors causing obstruction.
This could necessitate a cesarean section for safe delivery of the baby
(29). Postpartum hemorrhage is also more frequent in a myomatous uterus
(42), because of the inability of the uterus to contract and involute
completely, producing inadequate hemostasis. Despite all these possible
complications, several patients with large leiomyomas remain fertile,
become pregnant, and carry their fetus to term (9, 42).

D. Diagnosis
In asymptomatic patients, a leiomyoma might be detected as an
incidental finding during a gynecological exam, ultrasound, magnetic
resonance imaging (MRI) study, or on an abdominal x-ray, if calcification
has occurred. Some observant patients may notice an increase in abdominal
girth. Some previously asymptomatic leiomyomas may enlarge during
pregnancy, or with the use of exogenous estrogens, producing symptoms
leading to their detection. In patients with symptoms such as abnormal
uterine bleeding and pelvic pain or pressure (29), the clinical suspicion of
leiomyomas would be very high. This can be initially evaluated with a
pelvic exam, during which a uterine mass or nodularity may be palpated.
Diagnostic imaging procedures are used for additional non-invasive
work up. Ultrasonography (US) is usually the first imaging modality used in
the

evaluation

of

uterine

hysterosalpingography

(HSG),

leiomyomas.
and

MRI

Computed
are

also

tomography
used

to

(CT),

evaluate

leiomyomatous uteri. US is inexpensive, fast, and readily available (1) of
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the imaging modalities. The ultrasonographic criteria used to diagnose
leiomyomas include altered echo texture with inhomogeneity within the
uterus, and an enlarged uterus with an irregular contour (22, 38). US can be
used to distinguish between cystic and solid structures, and

can,

sometimes, give a reasonable estimation of the location of a leiomyoma
(1). However, the quality of the US scan is highly dependent on the
operator's expertise and the patient's habitus (26). Patients should have a
full bladder to facilitate scanning (1), and excessive bowel gas (52) can
block effective scanning. An enlarged uterus can also obscure adnexal
pathology (1, 38). Leiomyomas are frequently misdiagnosed with US.
Retroflexed uteri and uteri with developmental anomalies can cause
contour irregularities that can mask leiomyomas (22, 24). Degenerating
leiomyomas have been mistaken for fetal tissue (5). In one study, cystic
degeneration of leiomyomas were misdiagnosed as an abnormal gestational
sac - intrauterine location, and as an ectopic pregnancy - extrauterine
location (3). US is also relatively inaccurate in distinguishing between
subserosal pedunculated leiomyomas and extrauterine adnexal masses (22,
38) or posterior subserosal tumors and masses in the cul-de-sac (5). With
the advent of transvaginai ultrasonography (TVUS), imaging resolution and
detail has been greatly improved, and the limitations of

the patient's

habitus and bladder volume have been eliminated. However, the field of
view is very limited, so uterine

enlargement and volume cannot be

adequately assessed (41, 52). It also has a limited utility in children and
postmenopausal women due to the smaller vaginal size in these patients
(52). Although transabdominal US has inferior resolution when compared
with TVUS, it is usually considered adequate for diagnosis and follow up
of patients for whom no surgical intervention is planned.
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CT scanning has very limited utility in the evaluation of uterine
leiomyomas. It provides relatively poor tissue contrast, so uterine
anatomy can not be clearly defined, and leiomyomas usually can not be
accurately localized (33, 52). In addition to these disadvantages, ionizing
radiation and intravenous contrast are used (33, 52). MR I is currently the
optimal diagnostic modality for obtaining definitive information about
uterine leiomyomas, especially when US is indeterminate, or if surgery is
planned (13, 52, 61). MR! uses no ionizing radiation, and it is not as
operator dependent as US. It is noninvasive, and is only limited by patient
habitus when the patient is morbidly obese and cannot fit into the MR!
scanner. It provides excellent tissue contrast and uterine anatomic detail
(25, 36), and can be used to gain valuable information on the number,
location, classification, vascularity and degeneration of leiomyomas (33).
Three dimensional measurements can be obtained with ease, for use in
calculating uterine and tumor volumes (6, 35). Excellent resolution is
obtained with MR!, and tumors as small as 0.8 cm in diameter can be
confidently identified, compared with minimum tumor diameters of 1.1 cm
on US (61). MR! also has a wider field of view than US facilitating the
evaluation of massively enlarged uteri. Zawin et al. found that enlarged
uteri with volumes of 1429 cc could be measured with MR!, while the
maximum volume US could accurately measure was 140 cc (6!). Dudiak et
al. determined that MRI was better at detecting small tumors than US and
HSG (13). In one group of patients, MR! had a sensitivity of 91 %, compared
with 18% for HSG, in detecting abnormal uterine segments, in the same
study, when compared to US, MRI

sensitivity was 85%,

sensitivity was 69% (13). MRI

also

is

effective

in

while

US

distinguishing

leiomyomas from other solid tumors when US is indeterminate (52, 59).

MR!, however, does have some disadvantages, it is an expensive procedure,
it is also susceptible to image degradation due to patient motion (6, 3). CT
and

US

are

less

Claustrophobic
pacemakers,

susceptible

patients
intracranial

ferromagnetic

implants

cannot

to

this

of

MRI

scanning

undergo

vascular
that

type

could

clips
harm

(52),

image

and

patients,

degradation.
(52).
any

by

Cardiac
metallic

moving

or

malfunctioning under the magnetic force of the scanner, are major
contraindications to MRi scanning. Despite these drawbacks, MRi is still
the modality of choice for evaluating leiomyomas during hormonal theraoy
(61), infertility work ups (37), and prior to surgery (13). US can De used to
screen and follow up patients when no definitive treatment is planned
(mob, 52).

E. Treatment
Treatment of uterine leiomyomas depends on the patient's menstrual
status, the tumor size, the patient's wishes regarding fertility, and
whether or not the patient is symptomatic (9). Until recently, the only
options available were observation, with follow up, and surgery - either a
hysterectomy or a myomectomy. The current use of gonadotropin-releasing
hormone (GnRH) agonists provides a temporizing method for women who
wish to postpone, or avoid surgery. Patients who are asymptomatic, or
have only minor tolerable symptoms, with uterine size less than 10-12
weeks gestation can be followed every 3-6 months with pelvic exams and
US. This is usually adequate to monitor for rapid growth and complications
(9, 42). These patients rarely have

infertility problems due to the

leiomyomas

(9).

Surgery

is

usually

recommended

for

symptomatic

patients, for patients with uteri larger than 10-12 weeks (9), and for
patients whose adnexae can not be thoroughly evaluated because of the
enlarged uterus. Surgery is required for patients with rapid, unaccountable
growth of their leiomyomas, especially in postmenopausal women (9), in
whom the risk of malignancy is higher. A dilatation and curettage should
be followed by a hysterectomy in patients with abnormal uterine bleeding
(9, 42) and anemia which is refractory to iron replacement and hormonal
therapy.

The

definitive

treatment

for

uterine

leiomyomas

is

a

hysterectomy (19). Many patients are resistant to having hysterectomies
for various reasons, including the desire to preserve fertility (9),
menstrual function (42), and other personal and psychological reasons.
Myomectomies are also performed, but have the disadvantage of a 15-30%
leiomyoma recurrence rate (9,
possibility of major blood

loss

19). Both procedures also have the
(9,

42),

which

could

make

blood

transfusions necessary. This increases the patient's risk of infection with
the hepatitis or human immunodeficiency viruses. Postoperative adhesions
can cause further complications of bowel obstruction and pain.
GnRH agonists, such as leuprolide acetate have been shown to
decrease uterine and leiomyoma size, usually within 3-6 months of
treatment (11, 19, 51, 62). Symptoms associated with the leiomyomas,
such as pelvic pressure, pain, and menorrhagia were relieved (11, 19, 51),
and the vascularity of the tumors decreased (62). Friedman et al. found
that patients with large uteri who received preoperative therapy with
leuprolide acetate had decreased intraoperative blood loss when compared
to those who received placebo (20). The main disadvantage of treatment
with leuprolide acetate is that the uterus returns to the pretreatment size

within about 3-6 months after treatment is stopped (19, 51), although the
patients may remain symptom-free for several months longer (51). This
rapid regrowth may be due to an increased number of estrogen receptors
induced in the leiomyomatous tissues due to the hypoestrogenic action of
leuprolide acetate (48). It also has many side effects, including hot
flashes, mood changes, vaginal dryness and spotting, which are due to the
decreased estrogen levels (20, 51). These effects are uncomfortable, may
be tolerated (20, 51), but can be severe enough to cause premature
cessation of therapy (21). Since the decrease in uterine size is net
permanent, and growth recurs once the

leuprolide acetate has been

withdrawn, the drug is currently used as an adjunct to surgery.

It

decreases the leiomyoma size and vascularity, facilitating the surgical
removal and minimizing blood loss (11, 19, 20). The induced amenorrhea
reverses the anemia in patients with menorrhagia prior to treatment, also
decreasing the need for intraoperative blood transfusions (11, 19). it can
be used as a temporizing method for perimenopausai

women,

since

leiomyomas tend to regress after menopause (19, 51). It can also be used
in patients who are poor surgical risks (19), and in women who wish to
shrink their leiomyomas, and undergo a trial of conception before any
surgical intervention.
It is unfortunate that the only known cure for uterine leiomyomas is
a hysterectomy (19), however, each patient's treatment can be modified,
depending on their presenting symptoms, age, and personal concerns to
enable them to maintain a relatively normal lifestyle.
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1 i. MAGNETIC RESONANCE IMAGING

A. History
The phenomenon of nuclear magnetic resonance (NMR) was first
demonstrated by Bloch et al. (4), and Purcell et al. (47) working separately.
They called it "nuclear induction" (4, 47). Further studies continued, with
Odeblad and Lindstrom publishing a report on the first use of NMR on living
animal tissues in 1955 (44). In 1973, Lauterbur published the first account
of an image obtained with NMR (30). He produced an
containers of water (30). In 1976, the first image of

image of two
human tissue, a

finger, was produced by Mansfield and Maudsley (35). The field of NMR
imaging (NMRI), frequently referred to as MRI, continued to develop
rapidly, with increased utilization in humans. Extremely sophisticated and
powerful scanners have been built, with advanced and innovative imaging
techniques constantly being developed.

B. Basic Principles
The phenomenon of MRI is dependent on the magnetic qualities of
atomic nuclei (14). When nuclei have unpaired protons or neutrons, they
possess an intrinsic spin, and a magnetic moment (14, 53). In the absence
of an external magnetic field, the magnetic moments of the nuclei are
randomly oriented. However, when an external magnetic field is applied,
the nuclei become aligned with the direction of the field, because of their
magnetic moments (14, 46, 53). At equilibrium, this forms a net magnetic
moment of all

the nuclei

(14,

46).

The

nuclei

then

rotate

at

a

"precessional" or "resonant" frequency about the axis of the external field,
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the "z-axis" (14, 46), This frequency is determined by the type of nuclei,
and the strength of the magnetic field applied (14, 46, 53). These are
related by the Larmor equation:
V = y/2it*B0 ,

where v is the precessional frequency; X/2lt

is the gyrornagnetic ratio,

which is a constant that differs for each nucleus; and B0 is the magnetic
field strength.
Hydrogen is the most frequently used atom in MR imaging today (14,
53). It is a stable atom with a single proton, and is ubiquitous as a
component of water in the human body, except in compact bone where it is
present in decreased concentrations (34, 53). For these reasons, the
remaining discussion will focus on the use of the hydrogen nucleus
(proton) in medical imaging. The gyrornagnetic ratio for hydrogen is 42.577
megahertz ( MHz) at 1 Tesla (T) of field strength (46). The magnetic field
strength of most scanners used for medical imaging ranges from 0.02-2.0
T (46) These produce precessional frequencies in hydrogen of 0.2-84 MHz.
When a static magnetic field is generated in the scanner, the hydrogen
nuclei become oriented both parallel and antiparallel (53) to the z-axis
and this produces a large z-component of the net magnetization vector,

FI

(14). The x and y components are zero, because although all the protons
rotate at the same frequency, they are out of phase and therefore cancel
each other out. When radiofrequency (RF) waves at the precessional
frequency are directed at the nuclei in the x,y plane, the protons absorb
energy, and are rotated from the z-axis (14, 46) This process is called
excitation. These RF waves form excitation pulses which are characterized
by the amount of rotation from the z-axis they produce - a 90° pulse
rotates

FI from

the z-axis onto the x,y plane. This makes the

FTZ

component
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zero, while the MXy component increases (14). The resumption of the
equilibrium state from the excited state is called relaxation (14). it
consists of two components: the reconstitution of the Mz component, also
known as the spin-lattice relaxation, with a time constant Tl; and the
loss of the Mxy component, also called the spin-spin relaxation, with a
time constant T2 (14). During relaxation the protons emit the RF energy
they previously absorbed, and this is received as the MR signal (53). This
emission is the

Rxy

component of M (14). Three magnetic field gradients,

oriented perpendicular to each other, are superimposed on the static
magnetic field to provide spatial localization of the MR signal (33, 46, 53).
The magnitude of the MR signal is directly proportional to the proton
density in the tissue being scanned (53). The MR signal measured is always
less than the original amplitude absorbed, because of losses during T1 and
T2 relaxation (53). T1

relaxation

is

dependent

on

the

environment

surrounding the nucleus. As the excited nuclei return to equlibrium, they
dissipate some of the absorbed RF energy to the environment. T1 measures
this factor, and is the time, in milliseconds, for the recovery of 63% of the

FTZ

component (53). It varies with the static magnetic field of the scanner

(53). The T2 relaxation is due to variable inhomogeneity in the magnetic
field caused by identical adjacent nuclei interacting. It is the time, in
milliseconds, required for the Mxy component to be reduced by 37% of the
excitation level (53). T2 is independent of the magnetic field strength, but
is dependent on the chemical properties of the protons (53). The difference
between the T1 and T2 values of various tissues is an essential factor in
the production of image contrast (14).
Pulse sequences^consist of specific patterns of excitations and
listening times (14). Spin echo sequences are frequently used, and consist
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of an initial 90° excitation pulse, followed by a pause, then a

180°

excitation pulse is delivered. This serves to correct any inhomogeneity in
the magnetic field. The 130° pulse is followed by another pause, and then
there is a listening period (14, 33, 46). The sequence is repeated after the
listening period. The echo time, TE, is the time (milliseconds) between the
first pulse (90°) and the listening period. The repetition time, TR, is the
duration (milliseconds) of the entire pulse sequence before it is repeated
(14). Variations of the spin echo sequence, such as the inversion recovery,
!R, pulse sequence are also utilized. The !R pulse sequence consists of an
initial 180° pulse, followed by a pause, then a 90° pulse, then a pause,
another 180° pulse and finally, the listening period (14). Varying the pulse
sequences used will produce differences in the extent of the T1 or T2
weighting of the images obtained. The Mxy component is dependent on TE
and TR during excitation and relaxation (14). If the TE is prolonged, during
the listening period, there will be less

FlXy

and more Mz component.

Therefore, the T1 dependence is decreased, and T2 dependence is increased
(14). Increasing the TR (> 1500 msec), and the TE (> 60 msec) produces a
T2 weighted image. Shorter TR (< 300 msec) and TE values (< 40 msec)
produce T1 weighted images (14). Proton density dependent images have a
short TE, similar to T1 weighted images, but have a long TR, similar to the
T2 weighted images.

The TE and TR parameters chosen,

therefore,

influence the MR signal intensity, because they determine now much signal
is

received

after

excitation.

The MR

signal

intensity

is

therefore

dependent on Tl, T2, the proton density of the tissue, and the pulse
sequence being utilized.
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C. Image Production
Two dimensional MR images are produced for most medical purposes.
MR scanners use the two dimensional Fourier transformation method (33).
This involves the use of three weak magnetic gradients superimposed on
the static magnetic field. These are oriented in orthogonal directions. One
gradient, turned on during the 90° excitation pulse, is called the slice
select gradient (33). The RF pulse excites a certain predetermined volume
of protons, and in this way, the thickness of the slice is determined (33).
The second gradient is the phase encoding gradient. This enables the
location of the protons to be spatially encoded, due to changes in their
spin frequencies that occur under the effect of the gradient. These changes
cause the protons to fall out of the excitation phase induced by the 90°
pulse. The changed phase angles can be recorded and analyzed to determine
the location of the protons (33). The third gradient is called the frequency
encoding or readout gradient. This is activated during the echo reception
(listening period), and also causes changes in the proton frequencies. The
location of the protons along the gradient can then be determined by the
gradient strength, and the difference between the resonant frequency of
the static magnetic field and the new proton frequencies (33). Each slice
of tissue produces MR signal which is displayed in a map with the use of
pixels and voxels (14, 33). Each volume of tissue sampled forms a volume
element, or voxel. The length of the voxel corresponds to the slice
thickness. One surface of the voxel forms the picture element, or pixel
(33), and the signal from the entire voxel determines the signal intensity
of the image (14, 33). Each voxel corresponds to a specific pixel, several
of which are combined to form a signal intensity map in black and white
(14, 33), while the phase frequency information maps out spatial location

19

(33). Several projections ranging from 128 to 512 are obtained, repeated
and averaged to decrease data variation,and improve image resolution (14,
33). Spatial resolution depends on the number of pixels (the image matrix
size). The pixel size is affected by the size of the field of view (FOV), such
that the pixel size = FOV/rnatrix size (33). Since smaller pixel sizes
increase the spatial resolution, resolution can be improved by increasing
matrix size without changing the FOV (33). This will, however, increase
scanning

time.

Another

alternative

is

to

decrease

the

fov

while

maintaining the matrix size. This has the disadvantage of introducing
imaging artifacts and decreasing the signal to noise ratio, SNR (33). The
SNR reflects the ratio of MR signal to background noise. This can be
improved with signal averaging, and the use of

body surface coils. This

produces shortened scan times, and better spatial and contrast resolution
(33).
One major disadvantage of MR1 is the amount of scanning time
reguired. Scan time is the product of TR, the number of repetitions or
excitations performed, and the number of the views obtained (14, 33), and
can range from a few minutes to a few hours. It can be shortened bydecreasing TR, or cutting down the number of views and excitations.
However, each alternative has disadvantages such as decreased image SNR
(33) Techniques such as zero filling, echo planar and hybrid imaging, are
methods of decreasing the number of views in scanning. Driven equilibrium
and magnetic field gradient echo techniques are methods of decreasing TR,
but in addition to the decreased SNR, the images produced are also more T1
weighted (33). Most modern MR scanners have body surface coils, and other
adaptations that increase the SNR (33). This is making it possible for
several of the techniques mentioned above to be used to cut scan times
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without significant image degradation.
Artifacts can be introduced into MR! in several ways. External
objects emitting RF waves, ferromagnetic objects on, or in the patient
and voluntary or involuntary (cardiovascular, respiratory) patient motion
can all produce image artifacts (33, 53). These can be minimized by signal
averaging and gating techniques (33). Chemical shift and flow void
artifacts which are due to characteristics or rapid motion of the protons
being scanned also occur (33). Chemical shift artifacts can be decreased
by using special pulse sequences and steeper magnetic gradients (33). With
an understanding of how MR images are generated, it should be possible to
anticipate artifacts, and minimize them by adjusting imaging techniques.

D. Instrumentation
MRI scanners consist of a large main magnet, which may be either a
permanent magnet, an air core or iron core resistive magnet, or a
superconductive magnet (33). This produces the static magnetic field
which surrounds the patient. The three orthogonally oriented weaker
magnetic gradients are produced by three coaxial electromagnet coils (33,
46) that superimpose their fields on the static magnetic field. The RF
coils are planar or solenoidal coils which usually serve as both the
transmitter and receiver of the RF waves (33, 46) . The RF pulses received
are then transmitted through a spectrometer to a computer where the
image is generated (46).

E. Patient Safety Concerns
There are three main components of medical MR I which are being
investigated for possible adverse effects on humans with frequent and
prolonged exposure. These are the static magnetic fields (SMF), the
extremely low frequency magnetic fields (ELFMF), and the RF waves used
in imaging (46). There have been reports of patients with dental fillings
experiencing strange taste and pain sensations when exposed to SMF up to
1,5-2 T (46). There are, however, no reports of other detrimental effects
directly attributable to SMF exposure (7, 46). There is evidence that
neuronal stimulation or ventricular fibrillation can occur in some patients
exposed to the rapidly changing ELFMF generated by the gradient coils (46).
The RF waves generate heat in the patients' tissues, but this is usually
easily dissipated through the skin (46). Another problem associated with
the RF waves is interference with cardiac pacemaker functioning (46).
This problem can be avoided by careful patient screening and with new
developments in the manufacture of the pacemakers. Apart from these
cases, there is no evidence of increased morbidity or mortality with low
level exposure to RF waves (46, 49).
Other safety hazards in MR imaging include the previously discussed
effects of the magnetic fields on ferromagnetic objects,

such

as

aneurysmal clips and pacemakers which could rotate and harm the patient.
It is also difficult to monitor critically ill patients in the MR1 areas,
because of the limited space in the scanner, and the use of metal in most
monitoring devices (46).
Despite some valid safety concerns with MR1, most patients prefer
this imaging modality to CT scanning, because of the lack of ionizing
radiation and IV or oral contrast (46).
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F. MR 1 of the Female Pelvis
MR I is particularly well suited to the study of the female pelvis.
Multiple planes can be imaged without difficulty, it is noninvasive, and
does not involve the use of ionizing radiation. This eliminates concerns
about radiation effects on the female reproductive organs. Imaging of the
female pelvis is often done to distinguish between uterine and ovarian
pathology, and to obtain specific information about the location and type
of lesion in the uterus. By altering the TE and TR parameters, 71 or 72
weighted images can be obtained, producing excellent depictions of
anatomy and soft tissue differentiation. T1 weighted images are excellent
for differentiating between fat and smooth muscle (33), while 72
weighted images provide anatomic detail and contrast between soft
tissues. Tissues with short T1 values include fat, iron containing tissues
as occur in a subacute hemorrhage, and some proteinaceous fluids appear
bright on T1 weighted images (53). Tissues with long T1 values, such as
ligaments, tendons, cerebrospinal fluid, urine and cortical bone appear
darker on 71 weighted images (53). Muscle, inflammatory and neoplastic
tissue have an intermediate signal on 71 weighted Images. Cortical bone,
ligaments and tendons also have short T2 values, and have a low signal
intensity

on

T2

weighted

images,

while

iron

containing

tissues,

inflammation, fluids, and neoplastic tissues appear bright, due to their
long T2 values (33, 53). Fat has an intermediate signal intensity on T2
images (33).
The uterus in MR images appears as an organ with three intrinsic
layers - the endometrium, myometrium, and the junctional zone, which Is a
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low intensity layer only visualized with MR! (fig. I). The T1 values of
endometrium and myometrium are similar, so there is not much tissue
contrast on II weighted images (36). However, endometrium has a longer
T2 than myometrium, so it emits a brighter signal than the myometrium on
T2 weighted images. It is referred to as the endometrial stripe. MR! has
been used to study

the uterus during the menstrual

cycle, and the

endometrial stripe was observed to increase in thickness during the
follicular and secretory phases, corresponding appropriately with the
proliferative stage (28, 40). The changes in the endometrium under the
Influence of oral contraceptives (12) and GnRH analogs (40) have also been
studied with MR I.
The myometrium is a region of intermediate intensity on T2
weighted images. There is a thin layer of low Intensity between the
endometrium and the myometrium called the junctional

zone. Earlier

studies defined this region as either the stratum basale, vasculature (12,
25), or an area of flow void (31). However, a recent study by McCarthy et
al. has demonstrated that the junctional zone is probably a tissue layer,
within the myometrium, with a decreased water content, and low T2
values (39) (hence the low signal intensity on T2 weighted scans).
The cervix is usually visualized as a two layer region, with a
intermediate Intensity signal obtained from the external fibrous stroma,
and a bright central signal from the cervical mucus. There are venous plexi
around the cervix and upper vagina which emit a bright signal (37). The
vagina is also easily seen on T2 weighted Images as a central bright
signal, due to mucus, surrounded by an intermediate signal from the
fibromuscular walls. It is clearly distinct from the urethra (38). The
ovaries are easily identifiable on T2 weighted images, because of the

bright signal produced by the follicles (37).
Because of the

excellent

resolution

and

soft

tissue

contrast

obtained with MR I, it is possible to identify and accurately localize
pathologic lesions within the pelvis, and to differentiate between ovarian,
cul-de-sac, and uterine masses. It is also the technique of choice in
evaluating the uterus, enabling definitive diagnoses which are essential
for

the

appropriate

management

of

uterine

leiornyomatous

disease,

differentiating it from adenomyosis (57).
Although supported by little data, it has always been generally
accepted that certain characteristics of a leiornyomatous uterus, such as
tumor size,

type, degeneration

symptoms such as pain,

and

location

correlate

with

clinical

infertility, and spontaneous abortions. More

recently, Hricak et al. performed a study of 23 patients, which linked
disruption of the junctional zone, observed on MRI, with hypermenorrhea
(27). Their study, however, did not examine other MR! features of uterine
leiomyoma disease for correlation with clinical symptoms other than
hypermenorrhea. The purpose of this study

is to use

the

excellent

diagnostic capabilities of MRI, combined with patients' clinical histories,
to examine any possible correlation between leiomyoma characteristics
and patient symptoms and signs, such as menorrhagia, metrorrhagia,
abdominal/pelvic pain, back pain, dysmenorrhea, dyspareunia, infertility,
and spontaneous abortion.
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2. METHODS

!. PATIENT SELECTION

The study subjects were selected from a group of women who were
evaluated for uterine fibroid disease at the Yale Obstetrics and Gynecology
Infertility and Endocrine Clinic between October 1986 and December 1990.
45 patients were selected based on the following criteria:
Definite evidence of uterine leiomyomas on MR imaging - presence
of discrete rounded hypointense masses within the uterus.
A record of a clinical evaluation and an MRI study performed
within 0-60 days of each other.
The patients' age range was 25-54 years, with a mean age of 36.3 years. A
total of 1 14 clinical visits associated with concurrent MRI studies were
reviewed.

II. CLINICAL DATA COLLECTION

All the patients' charts were reviewed, and the following clinical
data were recorded from the histories obtained at the clinical visit:
The presence or absence of symptoms
The presence or absence of pain
The anatomic location of pain: abdominal/pelvic or back pain
The presence or absence of pressure
The presence or absence of 2° dysmenorrhea, or an increase in the

severity of 1° dysmenorrhea
The presence or absence of dyspareunia
The presence or absence of menorrhagia
The presence or absence of metrorrhagia
History of infertility
History of spontaneous abortion
Uterine size in gestational weeks from a bimanual exam
This data was then tabulated for subsequent analysis.

11. IMAGING TECHNIQUES

A total of 114 MRI studies performed between October 1986 and
December 1990 were reviewed. MR imaging was performed with a 1.5 T
Signa scanner (General Electric Medical Systems, Milwaukee). Spin echo
axial and sagittal images were obtained with two excitations, 28 cm FGV,
and a 128* 256 matrix. T1 weighted images were produced with a TR of
400-800 msec, and a TE of 20-40 msec with 5-10 millimeter (mm) thick
slices with 2.5-5.0 mm gaps. Intermediate and T2 weighted images were
obtained with a TR of 1500-2200 msec and a TE of 20/80 msec, using 5
mm thick slices, and 2.0-5.0 mm gaps. All the MRI studies obtained were
reviewed by a blinded investigator, (E.B.) who had no knowledge of the
patients' clinical data.

IV. MAGNETIC RESONANCE IMAGING DATA COLLECTION

The pelvic images were evaluated for total uterine volume, (TUV),
the presence of uterine leiomyomas, and various characteristics to be
described. All dimensions were measured manually with calipers. The
following information was amassed:
Three uterine dimensions, consisting of

the

anterior-posterior

diameter (AP), which was measured on sagittal images as the widest AP
thickness of the mid-corpus, the cranio-caudad height (CC), which was
obtained from sagittal views as the greatest length from (and Including)
the cervix to the top of the fundus, and the transaxial width (TR) which
was obtained from transaxial views as the widest measurement of the
uterine corpus. Subserosal leiomyomas projecting from, and distorting the
uterine contour were included in the maximum diameters. (Fig 2).
The dimensions, (AP,CC,TR) of the discrete countable leiomyomas
were obtained in the same planes as the uterine dimensions.if a leiomyoma
was spherical, and was measured in one image plane, but was absent in the
other planes due to scanning gaps, the single dimension obtained was used
in the volume calculations.
The locations of the leiomyomas within the uterus were recorded as
follows: body, fundus, cervix, broad ligament, and cornual. The category of
'‘multiple" was used when the leiomyomas were too many, and too small to
identify and measure with certainty.
The junctional zone appearance was categorized as present, intact
or disrupted.
The

type

of

leiomyoma

was

noted

as

follows:

submucosal

leiomyomas had the tumor epicenter in the submucosa, and were noted to

disrupt

the

contiguous

junctional

zone

(figs.

3

&

4);

intramural

leiomyomas had the epicenter in the myometrium, and did not disrupt the
junctional zone (figs. 5 & 6); subserosal leiomyomas had the epicenter in
the myometrium directly beneath the subserosa, with the bulk of the
tumor bulging into the subserosal layer (figs. 2 & 6).
Finally, the types of degenerative changes in the leiomyomas were
noted

based

on

the

tumors'

internal

signal.

The

degeneration

was

categorized as "non-specific", when the tumor had some signal increase
and inhomogeneity, which could not be definitely classified as fatty or
carneous

(figs.

2

-

6).

Although

this

probably

represented

hyaline

degenerative change, we did not classify it as such, since there are only a
few conclusive reports of a characteristic MR appearance for this type of
degeneration (27, 31), and we did not have histopathologic correlation
available. Carneous degeneration was diagnosed when there was a bright
signal within a tumor on 12 images, and an intermediate to bright signal
on Tl images, signifying a probable subacute hemorrhage (10, 23, 33, 55).
Fatty degeneration was identified when the tumor's internal signal was of
the same intensity as the subcutaneous fatty tissue. The category of "no
degeneration" was used when the leiomyoma had a homogeneous signal.

V. PAT! ENT/MR I SCAN PROFILE
The number of visit days per patient ranged from 1 -6 days. The mean
time between the 1 14MR1 studies and clinical visits was 14 days (range
of 0-51 days). Twenty-nine scans were performed on the same day as the
clinical visit, 30 scans were performed within 1-10 days of the clinical
visit, 29 scans were performed within 1 1-20 days of the clinical visit, 10

29

scans were performed within 21-30 days of the clinical visit, 10 scans
were performed within 31-40 days of the clinical visit, 5 scans were
performed within 41-50 days of the clinical visit, and
performed within 51

1

scan was

days of the clinical visit. Since the patients'

symptoms varied during their clinical evaluations, the MR I results were
re-evaluated for each consecutive scan, yielding a total of 317 MR!clinical data correlations. Twenty-nine out of the 45 patients in this study
were on leuproiide acetate for a portion of their clinical course; 5 of these
29 patients were

initially on placebo, and then elected to undergo

treatment with the drug after the study ended. Two patients received
placebo, but did not subsequently receive leuproiide acetate. (All the 31
patients described above were subjects in previous studies unrelated to
this current study). Fourteen patients did not receive any drug treatment.
A total of 47 scans were performed while patients were on leuproiide
acetate, and the remaining 57 scans comprised the no drug group. The data
obtained

when

patients

were

on

leuproiide

acetate

was

examined

separately from the placebo and the no drug group. The data obtained from
the placebo group was compared to the no drug group to detect any
differences in the clinical data due to a "placebo effect" on the subjective
information given by the patients. No significant differences in the results
were noted (p > 0.05), so the placebo group results were combined with the
no drug group results for further statistical analysis.
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Vi. PRELIMINARY DATA ANALYSIS

The uterine and
equation:

leiomyoma volumes were computed using

the

Volume (cc) = ‘Vjw * AP/2 x CC/2*TR/2 . The non-leiomyoma

uterine volume was obtained as the difference between the uterine volume
and the total

leiomyoma volume

estimations

by

bimanual

centimeters

above

the

exam

pubic

in

each

were

uterus.

expressed

symphysis.

Nine
as

These

uterine

the

size

number

measurements

of

were

converted to gestational weeks size, by referring to data compiled by
Baeyertz that related symphysio-fundal height in
gestational

age

127 women to the

in weeks of their fetuses (2). The uterine size

in

gestational weeks was converted to volume measurements with the use of
an equation derived by Flickinger et al (17):
Volume = 0.1 13w3 + 2.084w2 + 12.396w + 23.397
The uterine volumes obtained by MR! and bimanual exams were then
examined for any correlation. The MR! uterine volumes were plotted on a
graph

against

coefficient

the

was

metrorrhagia,

bimanual

calculated.

uterine
The

abdominal/pelvic

volumes,

clinical
pain,

and

findings

back

pain,

the
of

correlation
menorrhagia,

dysmenorrhea,

dyspareunia, infertility, and spontaneous abortion were correlated with
concurrent MR! findings of leiomyoma locations, types, degeneration, and
volumes, uterine volumes and junctional zone disruption. The significance
of the information obtained from these correlations was tested with chisquare analysis.

31

3. RESULTS

Forty-three of the 45 patients had one or more symptoms. The most
frequently

reported

abdominal/pelvic

symptom

pain,

was

metrorrhagia,

menorrhagia,
dysmenorrhea,

infertility, spontaneous abortion, and back pain (Table 1).

followed

by

dyspareunia,
The number of

leiomyomas per patient ranged from 1-10 discrete countable tumors, with
a total of 136 different leiomyomas for 43 of the patients. The two other
patients had tumors that were multiple, tiny (< 0.5 centimeters diameter)
and could not be counted.

TABLE 1.

Frequency of patients' symptoms and signs

Symptoms/Signs

Number of Patients (%)

Menorrhagia

32 (71%)

A/P Pain

23(51%)

Metrorrhagia

22(49%)

Dysmenorrhea

21(47%)

Dyspareunia

10(22%)

Infertility

10(22%)

Spontaneous Abortion

4

(9%)

Back Pain

2

(4%)
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I. JUNCTIONAL ZONE (JZ) DISRUPTION
The junctional zone on 1 1 1 scans clearly defined. The junctional
zone was not seen clearly enough on 3 scans to be categorized as intact or
disrupted.

Menorrhagia:
Leuprolide acetate
1/33 (3 %) of all scans with JZ disruption had menorrhagia.
1/10 (10%) of all scans with intact JZ had menorrhagia
p = 0.8822
No Drug Treatment
32/42 (76%) of all scans with JZ disruption had menorrhagia.
11/21 (52%) of all scans with intact JZ had menorrhagia.
p = 0.10J8
Leuprolide acetate compared to no drug treatment
1/33 (3 %) of all scans with JZ disruption on leuprolide acetate had
menorrhagia compared to 32/42 (75%) on no drug treatment.
p = 0.000/
1/10 (10%) of all scans with intact JZ

on leuprolide acetate had

menorrhagia compared to 11/21 (52%) on no drug treatment.
p = 0.06/5

Metrorrhagia:
Leuprolide acetate
13/33 (34%) of all scans with JZ disruption had metrorrhagia.
1/10(10%) of all scans with intact JZ had metrorrhagia.
p = 0.268
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Mo Drug Treatment
15/42 (36%) of all scans with JZ disruption had metrorrhagia.
3/21 (15%) of all scans with intact JZ had metrorrhagia.

p = 0.1J91
Leuproiide acetate compared to no drug treatment
13/38 (34 %) of all scans with JZ disruption on leuproiide acetate
had metrorrhagia compared to 15/42 (36%) on no drug treatment.

p = 0.9252
1/10 (10%) of all scans with intact JZ

on leuproiide acetate had

metrorrhagia compared to 3/21 (15%) on no drug treatment.

p = 0.8/0/

Spontaneous Abortion:
4/32 (13%) of patients with JZ

disruption

had

a

history

of

spontaneous abortion compared to 0/12 (0%) of patients with intact JZ.

p = 0.4866

Infertility:
11/29 (38%) of patients with disrupted JZ had

a

history

of

infertility compared to 1/10(10%) of patients with intact JZ.

p = 0.2 J 02

11. LEIOMYOMA LOCATION
The dominant leiomyoma within each uterus from each MR! study
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was evaluated for the location, which was then correlated with A/P and
back pain, pressure and infertility.

Pressure:
Leuprolide Acetate
3/33 (9%) of all scans with the dominant leiomyoma in the uterine
body had pressure.
0/2 (0%) of all scans with the dominant leiomyoma in the uterine
cervix had pressure.
2/8 (25%) of all scans with the dominant leiomyoma in the uterine
fundus had pressure.
0 scans had the dominant leiomyoma in the broad ligament.
0/3 (0%) of all scans with the dominant leiomyoma in multiple
uterine sites had pressure.
0 scans had no leiomyomas visualized.

p = 0.4999
No Drug Treatment
12/34 (47%) of all scans with the dominant leiomyoma in the
uterine body had pressure.
1/1 (100%) of all scans with the dominant leiomyoma in the uterine
cervix had pressure.
3/13 (23%) of all scans with the dominant leiomyoma in the uterine
fundus had pressure.
1/1 (100%) of all scans with the dominant leiomyoma in the broad
ligament had pressure.
1/7 (14%) of all scans with leiomyomas in multiple uterine sites
had pressure.

0/2 (0%) of all scans with no leiomyomas visualized had pressure.

p = 0.245J
Leuprolide acetate compared with no drug treatment
3/33 (9 %) of scans with the dominant leiomyoma in the uterine
body on leuprolide acetate had pressure compared with 12/34 (47%) of
scans on no drug treatment.

p = 0.0J56
0/2 (0 %) of scans with the dominant leiomyoma in the uterine
cervix on leuprolide acetate had pressure compared with 1/1 (100%) of
scans on no drug treatment.

p = 0.655
2/3 (25%) of scans with the dominant leiomyoma in the uterine
fundus on leuprolide acetate had pressure compared with 3/13 (23%) of
scans on no drug treatment.

p = 0.6694
0 scans had the dominant leiomyoma in the broad ligament on
leuprolide acetate.
0/3 (0%) of scans with the dominant leiomyoma in multiple uterine
sites on leuprolide acetate had pressure compared with 1/7 (14%) of scans
on no drug treatment.
0 scans had no leiomyomas visualized on leuprolide acetate.

p = 0.6455

Abdorninal/Pelvic Pain:
Leuprolide Acetate
7/33

(21%) of scans with the dominant leiomyoma in the uterine

body had abdominal/pelvic pain.
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0/2 (0%) of

scans with the dominant leiomyoma in the uterine

cervix had abdominal/pelvic pain.
2/8

(25%) of scans with the dominant leiomyoma m the uterine

fundus had abdominal/pelvic pain.
0 scans had leiomyomas in the broad ligament.
1/3 (33%) of scans with the dominant leiomyoma in multiple sites
had abdominal/pelvic pain.
0 scans had no leiomyomas visualized.
p = O.SJS
No Drug Treatment
14/34

(47%) of scans with the dominant leiomyoma in the uterine

body had abdominal/pelvic pain.
0/1 (0%) of

scans with the dominant leiomyoma in the uterine

cervix had abdominal/pelvic pain.
7/13 (54%) of scans with the dominant leiomyoma in the uterine
fundus had abdominal/pelvic pain.
0/1 (0%) of scans with the dominant leiomyoma in the broad
ligament had abdominal/pelvic pain.
4/7 (57%) of scans with the dominant leiomyoma in multiple sites
had abdominal/pelvic pain.
0/2

(0%)

of

scans

with

abdominal/pelvic pain.
p = 0.2J9

no

leiomyomas

visualized

had
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Leuprolide acetate compared to no drug treatment
7/33 (21%) of scans with the dominant leiomyoma in the uterine
body on leuprol ide acetate had abdominal/pelvic pain compared with 14/34
(47%) of scans on no drug treatment.
p = 0.4JS
0/2 (0 %) of scans with the dominant leiomyoma in the uterine
cervix on leuprolide acetate had abdominal/pelvic pain compared with 0/1
(0%) of scans on no drug treatment.
p = not calculable
2/8 (25%) of scans with the dominant leiomyoma in the uterine
fundus on leuprolide acetate had abdominal/pelvic pain compared with
7/13 (54%) of scans on no drug treatment.
p = 0.J991
0 scans had the dominant leiomyoma in the broad ligament on
leuprolide acetate.
1/3 (33%) of scans with the dominant leiomyoma in multiple uterine
sites on leuprolide acetate had abdominal/pelvic pain compared with 4/7
(57%) of scans on no drug treatment.
0 scans had no leiomyomas visualized on leuprolide acetate.
p = 0.6455

Sack Pain
Leuprolide Acetate
2/2 (100%) of scans with back pain had the dominant leiomyoma in
the uterine body.
No Drug Treatment
0 scans were associated with back pain.
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Infertility
6/32 (19%) of all patients with a dominant leiomyoma in the uterine
body had a prior history of infertility.
1/2 (50%) of all patients with a dominant leiomyoma in the uterine
cervix had a prior history of infertility.
3/9 (33%) of all patients with a dominant leiomyoma in the uterine
fundus had a prior history of infertility.
0/1 (0%) of all patients with a dominant leiomyoma in the broad
ligament had a prior history of infertility.
0/1 (0%) of all patients with a dominant leiomyoma in multiple
uterine sites had a prior history of infertility.
0 patients with leiomyomas that were not visualized had a history
of infertility.
p = 0.6752

III. LEIOMYOMA TYPE
The different types of leiomyomas (submucosal, intramural, and
subserosal) in each MRI study were

evaluated, and correlated with

menorrhagia, dysmenorrhea, infertility, and spontaneous abortion.

Infertility:
13/32 (41%) of patients with submucosal leiomyomas had a prior
history of infertility.

7/22 (32%) of patients with intramural leiomyomas had a prior
history of infertility.
2/11 (13%) of patients with subserosal leiomyomas had a priorhistory of infertility.
0/10 (0%) of patients with multiple leiomyomas had a prior history
of infertility.
3/9 (33%) of patients with no leiomyomas visualized had a prior
history of infertility.
p = 0.1441

Spontaneous Abortion:
4/32

(25%) of patients with submucosal leiomyomas had a prior

history of spontaneous abortion.
2/24 (3%) of patients with intramural leiomyomas had a prior
history of spontaneous abortion.
1/13 (7%) of patients with subserosal leiomyomas had a prior
history of spontaneous abortion.
0/10 (0%) of patients with multiple leiomyomas had a prior history
of infertility.
0/9 (0%) of patients with no leiomyomas visualized had a prior
history of spontaneous abortion.
p = 0.62! J

Dysmenorrhea:
Leuprolide Acetate
1/46 (2%) of all scans with at least 1 submucosal leiomyoma had
dysmenorrhea.
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2/23 (12%) of all scans with at least 1 intramural leiomyoma had
dysmenorrhea.
1/15 (7%) of all scans with at least 1 subserosal leiomyoma had
dysmenorrhea.
0/3 (0%) of all scans with multiple leiomyomas had dysmenorrhea.
0/5

(0%)

of

all

scans

with

no

leiomyomas

visualized

had

dysmenorrhea.
p = 0.7/26

No Drug Treatment
14/49 (29%) of all scans with at least 1 submucosal leiomyoma had
dysmenorrhea.
15/25 (60%) of all scans with at least 1 intramural leiomyoma had
dysmenorrhea.
5/19 (36%) of ail scans with at least 1 subserosal leiomyoma had
dysmenorrhea.
0/7 (0%) of all scans with multiple leiomyomas had dysmenorrhea.
3/3 (100%) of ail

scans with no

leiomyomas visualized had

dysmenorrhea.
p = 0.00/6

Leuorolide acetate compared to no drug treatment
1/46 (2%) of all scans with at least 1 submucosal leiomyoma on
leuprolide acetate had dysmenorrhea compared to 14/49 (29%) of scans
with no drug treatment.
p = 0.0012
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2/23 (12%) of all scans with at least 1 intramural leiomyoma on
leuprolide acetate had dysmenorrhea compared to 15/25 (60%) of scans
with no drug treatment.

p = 0.0006
1/15 (7%) of all scans with at least 1 subserosal leiomyoma on
leuprolide acetate had dysmenorrhea compared to 5/19 (36%) of scans
with no drug treatment.

p = 02987
0 scans with multiple leiomyomas had dysmenorrhea.
0/5 (0%) of all scans with no leiomyomas visualized on leuprolide
acetate had dysmenorrhea compared to 3/3 (100%) scans on no drug
treatment.

p = 0.038!

Menorrhagia:
Leuprolide Acetate
1/38 (3%) of all scans with at least 1 submucosal leiomyoma had
menorrhagia.
0/2 (0%) of all scans with at least 1 intramural leiomyoma had
menorrhagia.
0/4 (0%) of all scans with at least 1 subserosal leiomyoma had
menorrhagia.
0/2 (0%) of all scans with multiple leiomyomas had menorrhagia.
1/2 (50%) of all

scans

with

leiomyomas had menorrhagia.

p = 0.0255

both

intramural

and

subserosal
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No Drug Treatment
32/42 (76%) of all scans with at least 1 submucosal leiomyoma had
menorrhagia.
5/7 (71%) of all scans with at least 1 intramural leiomyoma had
menorrhagia.
3/6 (50%) of all scans with at least 1 subserosai leiomyoma had
menorrhagia.
0/5 (0%) of all scans with multiple leiomyomas had menorrhagia.
3/3 (100%) of all

scans with both

intramural

and subserosai

leiomyomas had menorrhagia.
p = 0.006J
Leuorolide acetate compared to no drug treatment
1/38 (3%) of all scans with at least 1 submucosal leiomyoma on
leuprolide acetate had menorrhagia compared to 32/42 (76%) of scans
with no drug treatment.
p = 00001
0/2 (0%) of all scans with at least 1

intramural leiomyoma on

leuprolide acetate had menorrhagia compared to 5/7 (71%) of scans with
no drug treatment.
p = 03241
0/4 (0%) of all scans with at least 1 subserosai leiomyoma on
leuprolide acetate had menorrhagia compared to 3/6 (50%) of scans with
no drug treatment.
p = 03241
0/2 (0%) of all scans with multiple leiomyomas on

leuprolide

acetate had menorrhagia compared to 0/5 (0%) scans on no drug treatment.
p = not calculable
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1/2 (50%) of all

scans

with

both

intramural

and

subserosa!

leiomyomas on leuprolide acetate had menorrhagia compared to 3/3 (100%)
of scans with no drug treatment.
p= 0.8195

IV. LEIOMYOMA DEGENERATION
A total of 296 leiomyomas were evaluated for any association
between degenerative changes, tumor volume and pain.

Leiomyoma Volume:
Leuprolide Acetate
1/85 (1%) of all the leiomyomas with volumes between 0-49.9 cc
had carneous degeneration.
3/17(18%) of all the leiomyomas with volumes between 50-99.9 cc
had carneous degeneration.
4/24(17%) of all the leiomyomas with volumes between 100-499.9
cc had carneous degeneration.
0/2 (0%) of all the leiomyomas with volumes between 500-999.9 cc
had carneous degeneration.
There were no leiomyomas with volumes between 1000-2200 cc.
p = 0.0071

No Drug Treatment
5/108 (5%) of all the leiomyomas with volumes between 0-49.9 cc
had carneous degeneration.
3/16 (19%) of all the leiomyomas with volumes between 50-99.9 cc
had carneous degeneration.
4/20 (20%) of all the leiomyomas with volumes between 100-499.9
cc had carneous degeneration.
4/14 (20%) of all the leiomyomas with volumes between 500-999.9
cc had carneous degeneration.
0/1 (0%) of all the leiomyomas with volumes between 1000-2200
had carneous degeneration.

p = 00/43
Leuprolide Acetate
51/85 (60%) of all the leiomyomas with volumes between 0-49.9 cc
had no degeneration.
0/17 (0%) of all the leiomyomas with volumes between 50-99.9 cc
had no degeneration.
0/24(0%) of all the leiomyomas with volumes between 100-499.9
cc had no degeneration.
0/2 (0%) of all the leiomyomas with volumes between 500-999.9 cc
had no degeneration.
There were no leiomyomas with volumes between 1000-2200 cc.

p = 0000/
No Drug Treatment
55/108 (51%) of all the leiomyomas with volumes between 0-49.9
cc had no degeneration.
3/16 (19%) of all the leiomyomas with volumes between 50-99.9 cc
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had no degeneration.
1/20 (5%) of all the leiomyomas with volumes between 100-499.9
cc had no degeneration.
0/14 (0%) of all the leiomyomas with volumes between 500-999.9
cc had no degeneration.
0/1 (0%) of all the leiomyomas with volumes between 1000-2200
had no degeneration.

p = 0.0001
Leuprolide Acetate
33/85 (39%) of all the leiomyomas with volumes between 0-49.9 cc
had non-specific degenerative changes.
14/17 (82%) of all the leiomyomas with volumes between 50-99.9
cc had non-specific degenerative changes.
20/24 (83%) of all the leiomyomas with volumes between 100499.9 cc had non-specific degenerative changes.
2/2 (100%) of all the leiomyomas with volumes between 500-999.9
cc had non-specific degenerative changes.
There were no leiomyomas with volumes between 1000-2200 cc.

p = 0.0001
No Drug Treatment
49/108 (45%) of all the leiomyomas with volumes between 0-49.9
cc had non-specific degenerative changes.
10/16 (63%) of all the leiomyomas with volumes between 50-99.9
cc had non-specific degenerative changes.
15/20 (75%) of all the leiomyomas with volumes between 100499.9 cc had non-specific degenerative changes.
10/14(71%) of all the leiomyomas with

volumes between 500-
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999.9 cc had non-specific degenerative changes.
1/1 (100%) of all the leiomyomas with

volumes between 1000-

2200 cc had non-specific degenerative changes.

p = 0.0442
Leuproiide acetate compared to no drug treatment
1/85 (1%) of leiomyomas with volumes between 0-49.9 cc on
leuproiide acetate had cameous degeneration compared to 5/108 (5%) on
no drug treatment.

p = 0.2J98
3/17 (18%) of leiomyomas with volumes between 50-99.9 cc on
leuproiide acetate had cameous degeneration compared to 3/15 (19%) on
no drug treatment.

p = 0.7! 18
4/24 (17%) of leiomyomas with volumes between 100-499.9 cc on
leuproiide acetate had cameous degeneration compared to 4/20 (20%) on
no drug treatment.

p= 09/48
0/2 (0%) of leiomyomas with volumes between 500-999.9 cc on
leuproiide acetate had cameous degeneration compared to 4/14 (29%) on
no drug treatment.

p = 1.0000
51/85 (60%) of leiomyomas with volumes between 0-49.9 cc on
leuproiide acetate had no degeneration compared to 55/108 (51%) on no
drug treatment.

p = 0.2661
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0/17 (0%) of leiomyomas with volumes between 50-99.9 cc on
leuprolide acetate had no degeneration compared to 3/16 (19%) on no drug
treatment.
p = 0.205J
0/24 (0%) of leiomyomas with volumes between 100-499 9 cc on
leuprol ide acetate had no degeneration compared to 1/20 (5%) on no drug
treatment.
p = 0.9264
0/2 (0%) of leiomyomas with volumes between 500-999.9 cc on
leuprol ide acetate had no degeneration compared to 0/14 (0%) on no drug
treatment.
p = not calculable
33/85 (39%) of leiomyomas with volumes between 0-49.9 cc on
leuprol ide acetate had non-specific degenerative changes compared to
49/108 (45%) on no drug treatment.

p = 0.4452
14/17 (82%) of leiomyomas with volumes between 50-99.9 cc on
leuprol ide acetate had non-specific degenerative changes compared to
10/16 (63%) on no drug treatment.
p = 0.J741
20/24(83%) of leiomyomas with volumes between 100-499.9 cc on
leuprol ide acetate had non-specific degenerative changes compared to
15/20 (75%) on no drug treatment.
p = 0.7588

A D

“HO

2/2 (! 00%) of leiomyomas with volumes between 500-999.9 cc on
leuprolide acetate had non-specific degenerative changes compared to
10/14(71%) on no drug treatment.
p = 1.0000

Abdominal/Pelvic Pain:
Leuprolide Acetate
1/8 (13%) of all the carneous leiomyomas were associated with
abdominal/pelvic pain.
13/51 (26%) of all the leiomyomas with no degeneration were
associated with abdominal/pelvic pain.
15/72 (21%) of all the leiomyomas with non-specific degenerative
changes were associated with abdominal/pelvic pain.
p= 06500
No Drug Treatment
9/16 (56%) of all the carneous leiomyomas were associated with
abdominal/pelvic pain.
13/59 (22%) of all the leiomyomas with no degeneration were
associated with abdominal/pelvic pain.
25/90 (28%) of all the leiomyomas with non-specific degenerative
changes were associated with abdominal/pelvic pain.
p - 00262
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Leuprol 1 de acetate compared to no drug treatment
1/8 (13%) of all the carneous leiomyomas on leuprolide acetate
were associated with abdominal/pelvic pain compared to 9/16 (56%) on no
drug treatment.
p = 0.1073
13/51 (26%) of all the leiomyomas with no degenerative changes on
leuprol ide acetate were associated with abdominal/pelvic pain compared
to 13/59 (22%) on no drug treatment.
p = 0.8411
15/72 (21%) of all the leiomyomas with non-specific degenerative
changes on leuprol ide acetate were associated with abdominal/pelvic pain
compared to 25/90 (28%) on no drug treatment.
p = 0.4036

Back Pain:
Only 2 leiomyomas in the entire study were associated with back
pain; both were on leuprol Ide acetate treatment, and had no degenerative
changes (2/59).

Dysmenorrhea:
Leuprolide Acetate
0/3 (0%) of ail the carneous leiomyomas were associated with
dysmenorrhea.
2/60 (3%) of all the

leiomyomas with no degeneration were

associated with dysmenorrhea.
3/72 (4%) of all the

leiomyomas with non-specific degenerative
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changes were associated with dysmenorrhea.
p - 0.8269
No Drug Treatment
9/!6 (56%) of all the carneous leiomyomas were associated with
dysmenorrhea.
25/71 (35%) of all the leiomyomas with no degeneration were
associated with dysmenorrhea.
30/90 (33%) of all the leiomyomas with non-specific degenerative
changes were associated with dysmenorrhea.
p = 0.075J
Leuprolide acetate compared to no drug treatment
0/8 (0%) of all the carneous leiomyomas on leuprolide acetate were
associated with dysmenorrhea compared to

9/16

(56%)

on

no

drug

treatment.
p = 0.025J
2/60 (3%) of all the leiomyomas with no degenerative changes on
leuprolide acetate were associated with dysmenorrhea compared to 25/71
(35%) on no drug treatment.
p = 0.001
3/72 (4%) of all the leiomyomas with non-specific degenerative
changes

on

leuprolide

acetate

were

associated

with

dysmenorrhea

compared to 30/90 (33%) on no drug treatment.
p = 0.1JJJ

Dvspareunia:
Leuprolide Acetate
0/8 (0%) of all the carneous leiomyomas were associated with
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dyspareunia.
6/60 (10%) of all the

leiomyomas with no degeneration were

associated with dyspareunia.
2/72 (3%) of ail the

leiomyomas with non-specific degenerative

changes were associated with dyspareunia.
p= 0.1586
No Drug Treatment
4/16 (25%) of all the carneous leiomyomas were associated with
dyspareunia.
12/71 (17%) of all the leiomyomas with no degeneration were
associated with dyspareunia.
9/90 (10%) of all the leiomyomas with non-specific degenerative
changes were associated with dyspareunia.
p

-

0.1946

Leuorolide acetate compared to no drug treatment
0/8 (0%) of all the carneous leiomyomas on ieuprolide acetate were
associated with dyspareunia compared to 4/16 (25%) on no drug treatment.
p = 0.JJ29
6/60 (10%) of all the leiomyomas with no degenerative changes on
Ieuprolide acetate were associated with dyspareunia compared to 12/71
(17%) on no drug treatment.
p = 0.J47J
2/72 (3%) of all the leiomyomas with non-specific degenerative
changes on Ieuprolide acetate were associated with dyspareunia compared
to 9/90 (10%) on no drug treatment.
p = 0. /JJJ
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V. TOTAL UTERINE VOLUME
The total uterine volumes from each MRI study measurements were
evaluated, and correlated with A/P pain and pressure.

Abdominal/Pelvic Pain:
Leuprolide Acetate
5/36 (14%) of scans with total uterine volume between 0-599.9 cc
were associated with abdominal/pelvic pain.
4/12 (33%) of scans with total uterine volume between 600-1 199.9
cc were associated with abdominal/pelvic pain.
p = 0.2857
No Drug Treatment
14/27 (52%) of scans with total uterine volume between 0-599.9 cc
were associated with abdominal/pelvic pain.
8/27 (30%) of scans with total uterine volume between 600-1 199.9
cc were associated with abdominal/pelvic pain.
3/8 (38%) of scans with total uterine volume between 1200-1799.9
cc were associated with abdominal/pelvic pain.
1/3 (33%) of scans with total uterine volume between 1800-2399.9
cc were associated with abdominal/pelvic pain.
0/1 (0%) of scans with total uterine volume between 2400-2999.9
cc were associated with abdominal/pelvic pain.
p

-

027/6
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Leuprolide Acetate compared to no drug treatment
5/36 (14%) of scans with total uterine volume between 0-599.9 cc
on

leuprolide

acetate

were

associated

with

abdominal/pelvic

pain

compared to 14/27 (52%) on no drug treatment.

p =0.0015
4/12 (33%) of scans with total uterine volume between 600-1 199.9
cc on leuprolide acetate were associated with abdominal/pelvic pain
compared to 8/27 (30%) on no drug treatment.

p =0.8851

Pressure:
Leuprolide Acetate
2/36 (6%) of scans with total uterine volume between 0-599.9 cc
were associated with pressure.
2/12 (16%) of scans with total uterine volume between 600-1 199.9
cc were associated with pressure.

p = 0.5464
No Drug Treatment
12/27 (44%) of scans with total uterine volume between 0-599.9 cc
were associated with pressure.
8/27 (30%) of scans with total uterine volume between 600-1 199.9
cc were associated with pressure.
1/8(13%) of scans with total uterine volume between 1200-1799.9
cc were associated with pressure.
0/3 (0%) of scans with total uterine volume between 1800-2399.9
cc were associated with pressure.
0/1 (0%) of scans with total uterine volume between 2400-2999.9

cc were associated with pressure.

p = 0.2591
Leuprolide Acetate compared to no drug treatment
2/36 (6%) of scans with total uterine volume between 0-599.9 cc on
leuprolide acetate were associated with pressure compared to

12/27

(44%) on no drug treatment.

p = 0.0005
2/12 (16%) of scans with total uterine volume between 600-1199.9
cc on leuprolide acetate were associated with pressure compared to 3/27
(30%) on no drug treatment.

p = 0.6467

VI. UTERINE NON-LEIOMYOMA VOLUME
To eliminate errors in analysis that would be introduced because of
the effect of leuprolide acetate on uterine and leiomyoma volumes, the
uterine volume measurements from the first MR! study of each patient,
performed without leuprolide acetate,

were used. These were then

correlated with spontaneous abortion and infertility.

Spontaneous Abortion:
2/22 (9%) of patients with uterine non-leiomyoma volume < 500 cc
had a history of spontaneous abortion.
1/12 (8%) of patients with uterine non-leiomyoma volume between
500-999.9 cc had a history of spontaneous abortion.
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0/2 (0%) of patients with uterine non-leiomyoma volume between
1000-1499.9 cc had a history of spontaneous abortion.

p = 09056

infertility:
4/22 (15%) of patients 'with uterine non-leiomyoma volume < 500 cc
had a history of infertility.
2/12 (17%) of patients with uterine non-leiomyoma volume between
500-999.9 cc had a history of infertility.
1/2 (50%) of patients with uterine non-leiomyoma volume between
1000-1499.9 cc had a history of infertility.

p = 0529

VII. TOTAL UTERI ME VOLUME BY BIMANUAL EXAM COMPARED WITH MR!
CALCULATED VOLUME
The uterine volume was calculated from

each

bimanual

exam

estimation, and for each MR! study measurement, as described previously
in the methods section. This data was then tabulated (Table 2), and
graphed (fig. 7) to determine any correlation.
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TABLE 2

Uterine

Volumes by MRI

measurements and gestational

size estimates.

GWK5 EQ
17
9.5
9
14
19.5
14.5
12.5
16.5
16

12
18
17
10.5
17.5

12
r\
0

15.5
9
18.5
8
18.5
/
16.5a
18
9
13.5^
6
153
13
13
5.5
1 3.5°
“7

10
9.5
6
26

MR! UT VOL/CC
849.1
895.3
61 1.4
479
981.3
868.2
872.5
1 1 15.3
920.2
592
1219.6
818.6
615.4
414.5
444.6
235.9
792.2
254.3
1086.9
327.7
994.3
403.2
237.4
864.6
507.7
506.6
401.9
353.3
297.2
244.9
200.8
804.5
635.9
784.4
720.2
2732.2

CALC UT VOL/CC
1391.6
426.1
386.1
915.5
1395.4
985.8
724.7
1302.9
1218.1
667.5
1580.3
1391.6
514.1
1484.2
667.5
313.8
1 137.0
386.1
1681.5
j

1 j>.8

1681.5
251.0
1302.9
1580.8
386.1
8-48.6
197.2
1059.6
785.0
785.0
173.4
843.6
468.8
426.1
197.2
3740.6

t n tr
1 Z.*J

12
15.5
1 1.5
7
20.5a
q
7
8
8
19.5a
16
14.5
13.5
19
10
1 c:
1 J

12
1 1.5a
18
12
17
15.5
8
10
1 1
16.5
15
19.5
13.5a
10
13
15.5
12.5
20.5a
15
9.5
8
24

294.3
362.3
481.7
334.9
319.4
789.8
364.7
282.6
312.2
159.3
802.6
944.8
584.1
993.3
1430.8
6! 1.2
900.4
481.3
149.7
1625.7
1014.4
714.4
559.1
237.8
531.9
316
1 090.2
377.3
1 173.3
205 5
474.8

724.7
667.5
1 1370
613.4
251.0
2126.8
386.1
251.0
3:3.8
TIT fi
nJ ! *J.U
1895.4
1218.1
985.8
848.6
1786.3
468.8
1059.6
667.5
613.4
1580.8
667.5
1391.6
1 137.0
313.8
463.8
562.3
1302.9
1059.6
1895.4
848.6
468.8

n 1 70 7Z i / Z. J

i bou.d

612.3
665.3
1066.5
1 104.2
313.4
264.3
1477.1

1 137.0
724.7
2126.8
1059.6
426.1
313.8
3083.4
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20
8.5
20
20
15
9
5.5
19.5
9.5

857.4
1077
1444.2
1350.5
1393
402.3
385.3
1350.1
390

0

o

OpQ O

17
18
9

588.8
1046.7
440

2008.9
1681.5
2008.9
2008.9
1059.6
386.1
1 7 j.4
1895.4
426.1
313.3
1391.6
1580.3
386.1

a Symphysio-fundal height was converted to gestational size in
weeks (2).
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Figure 7. Graph demonstrating the correlation
MR! uterine volumes (cc) with the uterine volumes
bimanual gestational age estimations.
y = 197.4 + 0.52x ; r = 0.77,
= 0.59.
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4.

Uterine

leiomyomas

D15CU5510N

have

always

been

associated

with

the

gynecological complications of menorrhagia, metrorrhagia, dysmenorrhea,
dyspareunia, pressure, abdominal/pelvic pain, infertility and spontaneous
abortion.

Menorrhagia

has

been

variously

attributed

to

leiomyoma

characteristics, such as submucosal tumor locations with endometrial
ulceration (9, 29. 42), mechanical interference with the uterine blood
supply (15, 16), and decreased uterine hemostasis due to the presence of
intramural

tumors

(42).

More

recently,

Hricak

et

al.

reported

hypermenorrhea in all of the 1 1 patients who had disruption of the MR!
detected junctional zone in her study (27). However, our results show no
statistically significant correlation between junctional zone disruption
(which

was

considered

equivalent

to

the

incidence

of

submucosal

leiomyomas in our study) and menorrhagia or metrorrhagia. When patients
with intact junctional zones were examined, the presence of intramural
leiomyomas was associated with menorrhagia in patients on no drug
treatment. This supports the theory that impaired uterine hemostasis,
which occurs as a result of decreased contraction due to the presence of
intramural leiomyomas, causes the increased bleeding (42). The relative
insignificance of the presence of submucosal leiomyomas is somewhat
contradictory to the results of Farber-Brown et al., which implied more of
a correlation with menorrhagia. However, their studies also confirmed
that intramural and even subserosal tumors can cause compression of the
blood vessels predisposing the patient to menorrhagia (15, 16). The

most

significant difference occurred between the LA treated and no drug

6

treatment groups, where LA was clearly effective in decreasing the
incidence of menorrhagia.

This is most likely due to its supressive

effects on the pituitary-ovarian axis , through its GnRH agonist-antagonist
actions. Since the patients are rendered arnenorrheic, their menorrhagia is
effectively eliminated.
Abdominal/pelvic pain and pressure are also frequent symptoms
associated with uterine leiomyomas. These are believed to be due to the
enlarged leiomyornatous uterus impinging on the

abdominal/pelvic organs

and nerves (29, 42) and stretching of pelvic adhesions. We evaluated total
uterine volume and the symptoms of pain and pressure in each patient, but
did not find any statistically significant relationship between them. This
is probably due to the fact that the sensation of pain or pressure is very
subjective, and depends more on the patients' tolerance levels and the rate
of growth of the tumor. Carneous leiomyomas were associated with A/P
pain in patients with no drug treatment. This differs from the results of
Persaud et al., who found no correlation between A/P pain and the
degenerative changes of leiomyomas on pathologic examination (45). The
association of carneous leiomyomas causing acute pain during pregnancy
has always been generally accepted (42). However, none of these patients
were pregnant. Treatment with LA decreased the incidence of pain in
patients with uterine volumes less than 500 cc, but did not have a
significant effect on the occurence of pain in patients with any type of
degenerated leiomyomas. This may be due to the fact that uterine volumes
in patients on LA represent a decrease from larger pretreatment volumes.
This decrease in uterine size is likely to eliminate, or at least diminish,
more serious complaints that existed previously - a subjective bias that
patients on no drug therapy would not exhibit. LA also decreased the

6

incidence of pressure in patients with a dominant leiomyoma in the
uterine body. The urinary bladder is in close proximity to the body of the
uterus, and patients are more likely to be sensitive to uterine volume
changes in this location.
Dysmenorrhea has been associated with cramping due to intramural
leiomyomas (42). This was observed in our patient group that did not
receive any LA. Patients, in both groups, with intramural tumors were
more likely to have dysmenorrhea than patients with subserosa! and
submucosal tumors. This increased cramping is probably due to the mass
of the intramural leiomyomas opposing contraction of the myometrium
during menses. Dysmenorrhea was again decreased in LA treated patients,
since they were amenorrheic. Dyspareunia is believed to be more common
in patients with cervical leiomyomas. Only two patients in our study had
cervical tumors, and neither patient complained of dyspareunia. This
number of patients is too small to generate a definite conclusion. The
effect of LA in decreasing the incidence of dyspareunia when uterine
volumes were less than 600 cc can also be explained (as above for A/P
pain) as a subjective feeling of improvement experienced by the patients
due to the decrease in uterine volume.
It is generally believed that the location or type of leiomyoma can
increase the incidence of infertility and spontaneous abortion (9). We did
not find any statistically significant relationship when we evaluated
junctional zone disruption, the location, and the type of leiomyoma in 12
patients with infertility and four patients with spontaneous abortion. We
also could not find any correlation

between

uterine

non-leiomyoma

volumes and infertility or spontaneous abortion. Since only about 2-10% of
infertility

problems

can

be

attributed

solely

to

the

presence

of

leiomyomas (9, 29), it is not too surprising that we were not able to
detect any definite relationship in the small patient sample that we
evaluated. It is, however, interesting that we had so few patients (4/45)
with a history of spontaneous abortion, since the incidence in women with
leiomyomas has been reported as high as 41% (9). It would seem logical
that as a result of decreased intrauterine volume and alteration of the
normal endometrium caused by the tumors (9), the patients might be more
prone to spontaneous abortions. However, several women with large
leiomyomas have had children without difficulty, so there are probably
other factors to be considered when fertility is being assessed in these
women.
We found that the type of degeneration that occurred in leiomyomas
was dependent on leiomyoma size. Smaller tumors tended to have either no
degenerative changes or a non-specific degenerative pattern which may
have been hyaline change, but we could not confirm this with pathologic
correlation. The larger tumors all had either non-specific or carneous
degeneration. Hricak et ai. made a similar observation relating the size of
the tumors to the presence of degeneration (27). This confirms the
association of degenerative changes with the growth of leiomyomas,
which causes a decrease in relative blood supply (42). Friedman et ai.
found a relationship between LA treatment and an increased incidence of
hyaline degeneration (20), but we did not find any such association with
any of the tumor degenerative changes that we noted.
W'e also compared the uterine volumes calculated from estimates of
gestational week size (17) to those calculated from MR! measurements.
Since no nomogram of MR! volumes of non-gravid enlarged uteri has been
constructed yet, we decided to assess how well the estimations from

pelvic examinations correlated with our MR! volumes. The two uterine
volumes correlated well, (fig. 7), with a correlation coefficient of 0.77,
and a coefficient of determination of 0.59. The estimations of gestational
week size can therefore be reliably predicted from MR! measurements
about 59% of the time. The 41% variability observed can be explained by
the fact that the pelvic examinations were performed by several different
people. Bimanual examinations have always been known to be relatively
inaccurate and unreliable, depending on the experience level of the
examiner. We obtained MR! volumes of 372.5 cc and 294.3 cc, both
corresponding to gestational sizes by examination of 12.5 weeks or 724.7
cc (Table 2). This further serves to illustrate the marked variation that
occurs with bimanual estimations of uterine size. The errors introduced by
the equation used to calculate the MR! uterine volume increase with the
more irregularly shaped uteri. It is important to be able to accurately
evaluate uterine volume, since it is often used by clinicians to make
therapeutic decisions, in patients who are already being evaluated with
MR!, this additional service could be made available if a standardized
nomogram were constructed.
This

is

the

first

comprehensive

study

to

examine

the

MR!

characteristics of uterine leiomyoma disease, and attempt to correlate
them with the clinical symptoms of the patients. The only significant MR,clinical correlations occurred between dysmenorrhea and intramural
tumors, degeneration and tumor size, and LA treated patients and patients
with no drug treatment. However, it is possible that if future studies were
to correlate each clinical symptom with more than one characteristic of
the leiomyomas, more statistically significant associations might be
found, and we would be closer to understanding the symptomatology of

uterine leiomyomas.
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FIGURES

Figure la. Sagittal T1 weighted (TR=400J TE=25) images of a normal
uterus demonstrating demarcation of the uterus OJ) from the surrounding
fat. No internal uterine anatomy is seen.

Figure lb. Sagittal T2 weighted (TR=2000, TE=30) images of the normal
uterus in la. Note the internal uterine anatomy. Endometrial stripe (E),
Junctional zone (J), Myometrium (M), Endocervical canal (C), Bladder (5).
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Figure

1c, Transverse T2 weighted (TR=2000, TE=30) images of the
normal uterus in la. Note the internal uterine anatomy. Endometrial stripe
(E), Junctional zone (J), Myometrium (M).
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Figure 2. Sagittal T2 weighted (TR-1700. TE=80) image of a subserosa!
cervical leiomyoma with an increased inhomogeneous interna! signal.
Endometrial stripe (E), Junctional zone (J), Myometrium (M), Endocervical
canal (C), Leiomyoma (L), Feeding vessel (arrow).
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Figure 3. Sagittal 12 (TR=1700, TE=80) weighted image demonstrating
splaying of the endometrial stripe (E) by two submucosal leiomyomas (L).
Note the increased signal of degenerative change in the larger leiomyoma
(arrow).
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Figure 4. Sagittal T2 weighted (TR= 1800, TE= 80) image demonstrating
an intramural leiomyoma (ID with a
junctional zone (arrow), and a large
Inhomogeneous increased signal in
(E),"junctional zone (J), Myometrium

submucosal component disrupting the
subserosal leiomyoma (SL) . Note the
both leiomyomas. Endometrial stripe
(M).
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Figure 5. Sagittal T2 weighted (TFM800, TE=60) image of intramural
leiomyoma (L) with inhomogeneous* increased signal Note the displaced
uterus and endometrial stripe (E).
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Figure 6. Transverse T2 (TR= 1700., TE= 80) weighted image of a large
subserosa] leiomyoma (5L) extending into the broad ligament. Note the
uterus is displaced to the right (U). Also note the intramural leiomyoma
(!L) with increased signal.
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